The South African Health Products Regulatory Authority (SAHPRA) has learned about the safety concerns regarding the presence of a nitrosamine impurity called NDMA in ranitidine-containing medicines. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on the results of...
SAHPRA is pleased to announce the appointment of a new Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, who will commence with this role in January 2020. Dr Semete-Makokotlela holds a Ph.D. in Biochemistry (North-West University) and an MSc in Management Finance and Investment from Wits Business...
Mr Khamusi Mutoti, Biological Medicine Manager at SAHPRA, was elected the Chairperson of the African Blood Regulator’s Forum (ABRF) during the African Medicines Regulation Conference (AMRC) held at Elephant Hill Hotel, Victoria Falls, Zimbabwe on 2 – 4 October 2019. Mr Mutoti who is also an...
MEDIA RELEASE: Embargo: Immediate release Warning - Illicit and dangerous erectile dysfunction medicines Pretoria, 28 June 2019 – The South African Health Products Regulatory Authority (SAHPRA) warns consumers not to buy illicit and dangerous medicines containing sildenafil, a substance used in the treatment of erectile dysfunction....
MEDIA RELEASE: Embargo: Immediate release NO RADIATION EXPOSURE AT KOPANONG HOSPITAL Pretoria, 21 June 2019 – The South African Health Products Regulatory Authority (SAHPRA) can confirm that there is NO radiation exposure emanating from the Kopanong Hospital in Vereeniging. “The principal mandate of SAHPRA is to...
MEDIA RELEASE: Embargo: Immediate release Pretoria, 2 July 2019 – The South African Health Products Authority (SAHPRA) is aware of the non-medicinal use of codeine-containing medicines and is working with the relevant bodies to combat this misuse. What is Codeine? Codeine is classified as an opioid. Opioids...
MEDIA RELEASE: For immediate release SAHPRA Backlog Project – the three-pronged approach Pretoria, 22 August 2019 – The South African Health Products Regulatory Authority (SAHPRA) aims to clear its backlog within a period of two years. The backlog clearance programme went live on 1 August...
MEDICINE SAFETY ALERT: PROMETHAZINE CONTRAINDICATED IN CHILDREN UNDER TWO YEARS OF AGE ...
MEDICINE SAFETY ALERT: ATYPICAL ANTIPSYCHOTICS IN ELDERLY PATIENTS WITH DEMENTIA ...
MEDICINE SAFETY ALERT: COUGH AND COLD MEDICINES NO LONGER TO BE USED ON CHILDREN UNDER THE AGE OF TWO YEARS ...